Literature DB >> 15220222

Restoration of cardiomyocyte functional properties by angiotensin II receptor blockade in diabetic rats.

Laura Raimondi1, Petra De Paoli, Edoardo Mannucci, Giuseppe Lonardo, Laura Sartiani, Grazia Banchelli, Renato Pirisino, Alessandro Mugelli, Elisabetta Cerbai.   

Abstract

Recent evidence suggests that blockade of the renin-angiotensin system ameliorates diabetes-induced cardiac dysfunction, but the mechanisms involved in this process remain elusive. We investigated the effect of treatment with an angiotensin II receptor blocker, losartan, on the metabolic and electrophysiological properties of cardiomyocytes isolated from streptozotocin-induced diabetic (STZ) rats. Glucose uptake and electrophysiological properties were measured in ventricular cardiomyocytes from normoglycemic and STZ-induced diabetic rats given vehicle or 20 mg x kg(-1) x day(-1) losartan for 8 weeks. Insulin and beta-adrenergic stimulation failed to increase the glucose uptake rate in STZ cardiomyocytes, whereas the alpha-adrenergic effect persisted. Concurrently, a typical prolongation of action potential duration (APD) and a decrease of transient outward current (I(to)) were recorded in patch-clamped STZ myocytes. Treatment with losartan did not affect body weight or glycemia of diabetic or control animals. However, in losartan-treated STZ-induced diabetic rats, beta-adrenergic-mediated enhancement of glucose uptake was completely recovered. APD and I(to) were similar to those measured in losartan-treated control rats. A significant (P < 0.0001) correlation between metabolic and electrophysiological parameters was found in control, diabetic, and losartan-treated diabetic rats. Thus, angiotensin receptor blockade protects the heart from the development of cellular alterations typically associated with diabetes. These data suggest that angiotensin receptor blockers may represent a new therapeutic strategy for diabetic cardiomyopathy.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15220222     DOI: 10.2337/diabetes.53.7.1927

Source DB:  PubMed          Journal:  Diabetes        ISSN: 0012-1797            Impact factor:   9.461


  19 in total

1.  Cannabinoid 1 receptor promotes cardiac dysfunction, oxidative stress, inflammation, and fibrosis in diabetic cardiomyopathy.

Authors:  Mohanraj Rajesh; Sándor Bátkai; Malek Kechrid; Partha Mukhopadhyay; Wen-Shin Lee; Béla Horváth; Eileen Holovac; Resat Cinar; Lucas Liaudet; Ken Mackie; György Haskó; Pál Pacher
Journal:  Diabetes       Date:  2012-02-07       Impact factor: 9.461

2.  No correlation between the p38 MAPK pathway and the contractile dysfunction in diabetic cardiomyocytes: hyperglycaemia-induced signalling and contractile function.

Authors:  Sibylle Wenzel; Golozar Soltanpour; Klaus-Dieter Schlüter
Journal:  Pflugers Arch       Date:  2005-07-23       Impact factor: 3.657

Review 3.  Diabetic cardiomyopathy: understanding the molecular and cellular basis to progress in diagnosis and treatment.

Authors:  Inês Falcão-Pires; Adelino F Leite-Moreira
Journal:  Heart Fail Rev       Date:  2012-05       Impact factor: 4.214

4.  Functional coupling of angiotensin II type 1 receptor with insulin resistance of energy substrate uptakes in immortalized cardiomyocytes (HL-1 cells).

Authors:  C Alfarano; L Sartiani; C Nediani; E Mannucci; A Mugelli; E Cerbai; L Raimondi
Journal:  Br J Pharmacol       Date:  2007-11-05       Impact factor: 8.739

5.  Cardiovascular and autonomic phenotype of db/db diabetic mice.

Authors:  Danielle Senador; Keerthy Kanakamedala; Maria Claudia Irigoyen; Mariana Morris; Khalid M Elased
Journal:  Exp Physiol       Date:  2009-02-13       Impact factor: 2.969

6.  Glutathione oxidation unmasks proarrhythmic vulnerability of chronically hyperglycemic guinea pigs.

Authors:  Chaoqin Xie; Nora Biary; Carlo G Tocchetti; Miguel A Aon; Nazareno Paolocci; Justin Kauffman; Fadi G Akar
Journal:  Am J Physiol Heart Circ Physiol       Date:  2013-02-01       Impact factor: 4.733

7.  Altered gene expression may underlie prolonged duration of the QT interval and ventricular action potential in streptozotocin-induced diabetic rat heart.

Authors:  F C Howarth; M Jacobson; M A Qureshi; M Shafiullah; R S Hameed; E Zilahi; A Al Haj; N Nowotny; E Adeghate
Journal:  Mol Cell Biochem       Date:  2009-03-08       Impact factor: 3.396

8.  Altered mechanical and electrical activities of the diabetic heart: Possible use of new therapeutics?

Authors:  Belma Turan; Mehmet Ugur; Semir Ozdemir; Nazmi Yaras
Journal:  Exp Clin Cardiol       Date:  2005

9.  Losartan counteracts the hyper-reactivity to angiotensin II and ROCK1 over-activation in aortas isolated from streptozotocin-injected diabetic rats.

Authors:  Paola Failli; Chiara Alfarano; Sergio Franchi-Micheli; Edoardo Mannucci; Elisabetta Cerbai; Alessandro Mugelli; Laura Raimondi
Journal:  Cardiovasc Diabetol       Date:  2009-06-22       Impact factor: 9.951

Review 10.  Diabetic cardiomyopathy.

Authors:  Omar Asghar; Ahmed Al-Sunni; Kaivan Khavandi; Ali Khavandi; Sarah Withers; Adam Greenstein; Anthony M Heagerty; Rayaz A Malik
Journal:  Clin Sci (Lond)       Date:  2009-05       Impact factor: 6.124

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.